Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

On the interaction of fluorophore-encapsulating PEGylated lecithin liposomes with hamster and human platelets.

Heger M, Salles II, van Vuure W, Hamelers IH, de Kroon AI, Deckmyn H, Beek JF.

Microvasc Res. 2009 Jun;78(1):57-66. doi: 10.1016/j.mvr.2009.02.006. Epub 2009 Mar 9.

PMID:
19281828
2.

High cytotoxicity of cisplatin nanocapsules in ovarian carcinoma cells depends on uptake by caveolae-mediated endocytosis.

Hamelers IH, Staffhorst RW, Voortman J, de Kruijff B, Reedijk J, van Bergen en Henegouwen PM, de Kroon AI.

Clin Cancer Res. 2009 Feb 15;15(4):1259-68. doi: 10.1158/1078-0432.CCR-08-1702.

3.

Antitumor activity and biodistribution of cisplatin nanocapsules in nude mice bearing human ovarian carcinoma xenografts.

Staffhorst RW, van der Born K, Erkelens CA, Hamelers IH, Peters GJ, Boven E, de Kroon AI.

Anticancer Drugs. 2008 Aug;19(7):721-7. doi: 10.1097/CAD.0b013e328304355f.

PMID:
18594214
4.

Nanocapsules: a novel lipid formulation platform for platinum-based anti-cancer drugs.

Hamelers IH, de Kroon AI.

J Liposome Res. 2007;17(3-4):183-9.

PMID:
18027238
5.

Carboplatin nanocapsules: a highly cytotoxic, phospholipid-based formulation of carboplatin.

Hamelers IH, van Loenen E, Staffhorst RW, de Kruijff B, de Kroon AI.

Mol Cancer Ther. 2006 Aug;5(8):2007-12.

6.

Impaired cisplatin influx in an A2780 mutant cell line: evidence for a putative, cis-configuration-specific, platinum influx transporter.

Helleman J, Burger H, Hamelers IH, Boersma AW, de Kroon AI, Stoter G, Nooter K.

Cancer Biol Ther. 2006 Aug;5(8):943-9. Epub 2006 Aug 2.

PMID:
16775422
7.

The Rac activator Tiam1 is required for (alpha)3(beta)1-mediated laminin-5 deposition, cell spreading, and cell migration.

Hamelers IH, Olivo C, Mertens AE, Pegtel DM, van der Kammen RA, Sonnenberg A, Collard JG.

J Cell Biol. 2005 Dec 5;171(5):871-81.

8.

17beta-Estradiol responsiveness of MCF-7 laboratory strains is dependent on an autocrine signal activating the IGF type I receptor.

Hamelers IH, Van Schaik RF, Sussenbach JS, Steenbergh PH.

Cancer Cell Int. 2003 Jul 11;3(1):10.

9.

Interactions between estrogen and insulin-like growth factor signaling pathways in human breast tumor cells.

Hamelers IH, Steenbergh PH.

Endocr Relat Cancer. 2003 Jun;10(2):331-45. Review.

PMID:
12790794
10.

Insulin-like growth factor I triggers nuclear accumulation of cyclin D1 in MCF-7S breast cancer cells.

Hamelers IH, van Schaik RF, Sipkema J, Sussenbach JS, Steenbergh PH.

J Biol Chem. 2002 Dec 6;277(49):47645-52. Epub 2002 Oct 2.

11.

Synergistic proliferative action of insulin-like growth factor I and 17 beta-estradiol in MCF-7S breast tumor cells.

Hamelers IH, van Schaik RF, van Teeffelen HA, Sussenbach JS, Steenbergh PH.

Exp Cell Res. 2002 Feb 1;273(1):107-17.

PMID:
11795951
12.

Stabilization of cyclin D1 mRNA via the phosphatidylinositol 3-kinase pathway in MCF-7 human breast cancer cells.

Dufourny B, van Teeffelen HA, Hamelers IH, Sussenbach JS, Steenbergh PH.

J Endocrinol. 2000 Aug;166(2):329-38.

PMID:
10927622
13.

Supplemental Content

Loading ...
Support Center